The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Bristol-Myers Squibb; Pfizer (I)
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: CheckMate 7FL.
 
Sherene Loi
Consulting or Advisory Role - Aduro Biotech (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Heather L. McArthur
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Genomic Health; Immunomedics; Lilly; Merck; Pfizer; Puma Biotechnology; Puma Biotechnology; Seagen
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); ZIOPHARM Oncology (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; DAVA Pharmaceuticals; Genentech; Immunomedics; Lilly; Lilly; Lilly; Lilly; Merck; Pfizer; Puma Biotechnology; Spectrum Pharmaceuticals
Other Relationship - Genomic Health; Lilly
 
Nadia Harbeck
Stock and Other Ownership Interests - West German Study Group
Honoraria - Amgen; AstraZeneca; Genomic Health; Novartis; Pfizer; Pierre Fabre; Roche; Zodiac Pharma
Consulting or Advisory Role - Agendia; AstraZeneca; Celgene; Daiichi Sankyo; Lilly; Merck Sharp & Dohme; Novartis; Odonate Therapeutics; Pfizer; Pierre Fabre; Roche/Genentech; Sandoz; Seagen; West German Study Group (I)
Research Funding - Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Lajos Pusztai
Consulting or Advisory Role - Almac Diagnostics; AstraZeneca; Athenex; Bristol-Myers Squibb; Clovis Oncology; Eisai; H3 Biomedicine; Immunomedics; Merck; Novartis; Roche/Genentech; Seagen; Syndax
Research Funding - AstraZeneca (Inst); Genentech (Inst); Merck (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca
(OPTIONAL) Uncompensated Relationships - NanoString Technologies
 
Suzette Delaloge
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Kristen Letrent
Employment - Bristol-Myers Squibb
 
Tian Chen
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - COMBINATION THERAPY WITH ANTI-IL-8 ANTIBODIES AND ANTI-PD-1 ANTIBODIES FOR TREATING CANCER
 
Bin Li
No Relationships to Disclose
 
Kay Tatsuoka
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Dimitrios Zardavas
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Giuseppe Curigliano
Honoraria - Ellipses Pharma
Consulting or Advisory Role - Bristol-Myers Squibb; Foundation Medicine; Lilly; Novartis; Pfizer; Roche/Genentech; Samsung
Speakers' Bureau - Daiichi Sankyo; Foundation Medicine; Lilly; Novartis; Pfizer; Roche/Genentech; Samsung
Travel, Accommodations, Expenses - Pfizer; Roche/Genentech